FiercePharma

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Medscape

Short-Term Safety and Tolerability of Double-Dose Salmeterol/Fluticasone Propionate in Adult Asthmatic Patients

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Finanznachrichten

Novartis International AG: AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus[1] in persistence to treatment

Novartis International AG / AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus® [1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The ...
PharmaTimes

INSPIRE tips the balance for Seretide in COPD mortality

Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...
Medscape

Short-Term Safety and Tolerability of Double-Dose Salmeterol/Fluticasone Propionate in Adult Asthmatic Patients

This study has demonstrated that doubling the dose of Seretide™ administered via the Diskus™ inhaler over a short period is safe and well tolerated. Whilst this is not a recommended treatment approach ...